Cargando…
Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review
Obstructive airway disease (OAD), which includes COPD and asthma, is the leading cause of morbidity and mortality in India. Long-acting bronchodilators (long-acting β2 agonists (LABAs) and/or long-acting muscarinic antagonists (LAMAs)) and inhaled corticosteroids (ICS) have a vital role in the manag...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958219/ https://www.ncbi.nlm.nih.gov/pubmed/35350278 http://dx.doi.org/10.1183/23120541.00556-2021 |
_version_ | 1784676901829214208 |
---|---|
author | Dhar, Raja Talwar, Deepak Salvi, Sundeep Muralimohan, B.V. Panchal, Sagar Patil, Saiprasad Bhagat, Sagar Khatri, Nishtha Barkate, Hanmant |
author_facet | Dhar, Raja Talwar, Deepak Salvi, Sundeep Muralimohan, B.V. Panchal, Sagar Patil, Saiprasad Bhagat, Sagar Khatri, Nishtha Barkate, Hanmant |
author_sort | Dhar, Raja |
collection | PubMed |
description | Obstructive airway disease (OAD), which includes COPD and asthma, is the leading cause of morbidity and mortality in India. Long-acting bronchodilators (long-acting β2 agonists (LABAs) and/or long-acting muscarinic antagonists (LAMAs)) and inhaled corticosteroids (ICS) have a vital role in the management of patients with OAD. While symptom burden and exacerbations are common amongst treated patients, poor adherence to inhaler therapy is a frequent challenge. Better treatment options that optimise symptom control, improve quality of life, reduce exacerbation risk and improve adherence are desired. Triple therapy (ICS/LABA/LAMA) is recommended in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021 guidelines for symptomatic COPD patients on ICS/LABA or LABA/LAMA, and who are at increased risk for frequent or severe exacerbations. Similarly, add-on LAMA is recommended in uncontrolled asthma patients on medium- to high-dose ICS/LABA by the Global Initiative for Asthma (GINA) 2021 guideline. In the real world, high-risk and overlapping phenotypes exist, which necessitate early initiation of triple therapy. We aim to provide an expert review on the use of single-inhaler triple therapy (SITT) for OAD management in global and Indian settings, knowledge from which can be extrapolated for appropriate treatment of Indian patients. The OAD population in India may benefit from early optimisation to SITT characterised by a high burden of exacerbating OAD, nonsmoker COPD and asthma–COPD overlap. |
format | Online Article Text |
id | pubmed-8958219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-89582192022-03-28 Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review Dhar, Raja Talwar, Deepak Salvi, Sundeep Muralimohan, B.V. Panchal, Sagar Patil, Saiprasad Bhagat, Sagar Khatri, Nishtha Barkate, Hanmant ERJ Open Res Reviews Obstructive airway disease (OAD), which includes COPD and asthma, is the leading cause of morbidity and mortality in India. Long-acting bronchodilators (long-acting β2 agonists (LABAs) and/or long-acting muscarinic antagonists (LAMAs)) and inhaled corticosteroids (ICS) have a vital role in the management of patients with OAD. While symptom burden and exacerbations are common amongst treated patients, poor adherence to inhaler therapy is a frequent challenge. Better treatment options that optimise symptom control, improve quality of life, reduce exacerbation risk and improve adherence are desired. Triple therapy (ICS/LABA/LAMA) is recommended in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021 guidelines for symptomatic COPD patients on ICS/LABA or LABA/LAMA, and who are at increased risk for frequent or severe exacerbations. Similarly, add-on LAMA is recommended in uncontrolled asthma patients on medium- to high-dose ICS/LABA by the Global Initiative for Asthma (GINA) 2021 guideline. In the real world, high-risk and overlapping phenotypes exist, which necessitate early initiation of triple therapy. We aim to provide an expert review on the use of single-inhaler triple therapy (SITT) for OAD management in global and Indian settings, knowledge from which can be extrapolated for appropriate treatment of Indian patients. The OAD population in India may benefit from early optimisation to SITT characterised by a high burden of exacerbating OAD, nonsmoker COPD and asthma–COPD overlap. European Respiratory Society 2022-03-28 /pmc/articles/PMC8958219/ /pubmed/35350278 http://dx.doi.org/10.1183/23120541.00556-2021 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Reviews Dhar, Raja Talwar, Deepak Salvi, Sundeep Muralimohan, B.V. Panchal, Sagar Patil, Saiprasad Bhagat, Sagar Khatri, Nishtha Barkate, Hanmant Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review |
title | Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review |
title_full | Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review |
title_fullStr | Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review |
title_full_unstemmed | Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review |
title_short | Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review |
title_sort | use of single-inhaler triple therapy in the management of obstructive airway disease: indian medical experts’ review |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958219/ https://www.ncbi.nlm.nih.gov/pubmed/35350278 http://dx.doi.org/10.1183/23120541.00556-2021 |
work_keys_str_mv | AT dharraja useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview AT talwardeepak useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview AT salvisundeep useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview AT muralimohanbv useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview AT panchalsagar useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview AT patilsaiprasad useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview AT bhagatsagar useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview AT khatrinishtha useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview AT barkatehanmant useofsingleinhalertripletherapyinthemanagementofobstructiveairwaydiseaseindianmedicalexpertsreview |